The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
protopanaxadiol results in increased expression of and results in decreased phosphorylation of CDC25A protein protopanaxadiol results in increased expression of CDC25A mRNA
protopanaxadiol results in increased expression of CDC25C mRNA protopanaxadiol affects the expression of and affects the phosphorylation of CDC25C protein
protopanaxadiol results in decreased expression of and results in increased phosphorylation of EGFR protein protopanaxadiol results in decreased activity of EGFR protein
ginsenoside Rg3 results in increased degradation of AR protein ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]
ginsenoside Rg3 results in increased cleavage of CASP3 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein]
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein] ginsenoside Rg3 results in decreased expression of FUT4 protein
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein] ginsenoside Rg3 results in decreased expression of HSF1 protein
ginsenoside Rg3 results in increased expression of IL1B protein ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 mRNA]; ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein ginsenoside Rg3 results in increased activity of NFKB1 protein
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]
Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein] ginsenoside Rg3 results in increased expression of NOS2 mRNA
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]
ginsenoside Rg3 results in increased cleavage of PARP1 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein]
ginsenoside Rg3 results in decreased expression of PROM1 mRNA XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein ginsenoside Rg3 results in decreased expression of and results in decreased phosphorylation of RELA protein
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] 3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]
ginsenoside Rg3 results in increased expression of TNF protein ginsenoside Rg3 inhibits the reaction [dimethoxon results in increased expression of TNF protein] ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein
[allocholic acid co-treated with 1-Naphthylisothiocyanate] results in decreased expression of CYP8B1 protein; allocholic acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]
[NR1I2 protein affects the susceptibility to Pregnenolone Carbonitrile] which affects the abundance of allocholic acid; allocholic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NR1I2 mRNA]
Cholic Acid results in increased expression of ABCA1 mRNA [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA
Cholic Acid results in increased expression of ABCB11 mRNA Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein Cholic Acid results in decreased activity of ABCB11 protein Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA] [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA
ABCB4 affects the secretion of Cholic Acid Cholic Acid results in increased expression of ABCB4 mRNA epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA]
Cholic Acid results in increased expression of ABCC2 mRNA Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA
Cholic Acid results in increased expression of ABCG5 mRNA [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA
Cholic Acid results in increased expression of ABCG8 mRNA [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA]
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein]
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid] AHR gene mutant form results in increased secretion of Cholic Acid AHR gene mutant form results in increased abundance of Cholic Acid
Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein]
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein]
[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein]
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein Cholic Acid results in increased expression of CCND1 protein
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]
Cholic Acid results in decreased expression of CDKN1A protein [Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA]
Cholic Acid results in decreased activity of CYP3A2 protein [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid Cholic Acid metabolite results in decreased activity of CYP3A4 protein Cholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA Cholic Acid results in decreased expression of CYP7A1 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA]
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter Cholic Acid results in increased expression of FGF15 mRNA Cholic Acid results in increased expression of FGF19 mRNA
Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]]
Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]]
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]
[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]
[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]
[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]
Cholic Acid results in increased expression of LRP2 protein NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein Cholic Acid results in increased activity of MAPK1 protein
[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein Cholic Acid results in increased activity of MAPK3 protein
Cholic Acid results in increased phosphorylation of NFKBIA protein Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA Cholic Acid results in increased expression of NR0B2 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA]
Cholic Acid binds to NR1H4 protein Cholic Acid results in decreased expression of NR1H4 mRNA Cholic Acid results in increased phosphorylation of NR1H4 protein Cholic Acid results in increased expression of NR1H4 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein] [[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein [Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein
Cholic Acid results in increased expression of NR1I2 mRNA Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein
Cholic Acid results in increased expression of PCNA protein [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein
Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein [Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]
PPARA gene mutant form results in decreased abundance of Cholic Acid [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA]
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein
Cholic Acid results in decreased expression of SLC10A2 mRNA Cholic Acid affects the expression of SLC10A2 mRNA Cholic Acid results in decreased expression of SLC10A2 protein
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA Cholic Acid results in increased expression of SLC51B mRNA
SLCO1B2 protein results in increased uptake of Cholic Acid Cholic Acid results in increased expression of SLCO1B3 mRNA SLCO1B3 protein results in increased uptake of Cholic Acid Cholic Acid results in increased expression of SLCO1B2 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA]
Cholic Acid results in increased expression of TNF mRNA Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein]
Digoxigenin results in increased expression of RORC mRNA Digoxigenin promotes the reaction [RORC protein binds to G6PC1 promoter]; Digoxigenin promotes the reaction [RORC protein binds to NPAS2 promoter]; RORC protein promotes the reaction [Digoxigenin results in increased expression of RORC mRNA]
[ginsenoside compound K co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside compound K promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside compound K inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside compound K inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside compound K results in decreased expression of TNF mRNA ginsenoside compound K results in decreased susceptibility to TNF protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL18 protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL18 protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL1B protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL1B protein]
Chloroquine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]]; ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]] ginsenoside Rb1 results in decreased expression of SQSTM1 protein
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA]
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein]
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] ginsenoside Re results in decreased expression of AIF1 protein
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein]
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein]
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein]
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein ginsenoside Re results in increased phosphorylation of MAPK1 protein
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein ginsenoside Re results in increased phosphorylation of MAPK3 protein
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ginsenoside Re results in decreased expression of NOS2 protein
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein]
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re
ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein] ginsenoside Re results in decreased expression of PTAFR protein
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]
ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein
ginsenoside Re results in decreased expression of SCD mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA]
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein
SLCO1B2 protein binds to and results in increased transport of ginsenoside Re SLCO1B3 protein binds to and results in increased transport of ginsenoside Re
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re results in decreased activity of SOD1 protein
ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]]
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein]
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]]
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein]
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein] ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA]
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]
ginsenoside Rg1 results in increased expression of BAX protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA] ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein
ginsenoside Rg1 results in increased activity of CASP9 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein]
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA]
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein]
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein]
ABCB11 protein affects the transport of Glycocholic Acid [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA
Glycocholic Acid results in increased activity of NR1H4 protein [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA
gypenoside LXXV results in increased phosphorylation of AKT1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased phosphorylation of AKT1 protein]
gypenoside LXXV results in increased expression of and results in increased secretion of CTGF protein gypenoside LXXV results in increased expression of CTGF mRNA
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]
gypenoside LXXV results in decreased phosphorylation of IRS1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein]; gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]
gypenoside LXXV results in increased expression of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV binds to and results in increased activity of PPARG protein]; gypenoside LXXV binds to and results in increased activity of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of PPARG protein]
gypenoside LXXV affects the localization of SLC2A4 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of SLC2A4 protein]
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]; gypenoside LXXV inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
[CYP3A4 protein results in increased hydroxylation of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid
UGT2B7 protein alternative form results in increased glucuronidation of hyodeoxycholic acid; UGT2B7 protein results in increased glucuronidation of hyodeoxycholic acid [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid UGT2B7 protein results in increased glycosylation of hyodeoxycholic acid UGT2B7 protein affects the metabolism of hyodeoxycholic acid
notoginsenoside R1 results in increased expression of ABCB1 mRNA notoginsenoside R1 results in increased expression of ABCB1A mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] notoginsenoside R1 inhibits the reaction [Acrylamide results in increased expression of CASP9 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein]
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein]
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein]
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein]
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein]
[notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein; notoginsenoside R1 results in increased phosphorylation of JAK1 protein
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]
notoginsenoside R1 results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased expression of MCL1 protein notoginsenoside R1 results in increased activity of MCL1 promoter [notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; cryptotanshinone inhibits the reaction [notoginsenoside R1 results in increased expression of MCL1 protein]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein
notoginsenoside R1 affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein]
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] notoginsenoside R1 results in increased activity of NR1I2 protein NR1I2 protein results in increased susceptibility to notoginsenoside R1
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein]
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein]
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]
[notoginsenoside R1 results in increased phosphorylation of STAT3 protein] which results in increased expression of MCL1 mRNA; notoginsenoside R1 results in increased phosphorylation of and results in increased localization of STAT3 protein [notoginsenoside R1 results in increased phosphorylation of JAK1 protein] which results in increased phosphorylation of STAT3 protein
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 results in decreased expression of TNF 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein]
notoginsenoside R1 results in increased expression of TXN1 protein notoginsenoside R1 inhibits the reaction [Acrylamide results in decreased expression of TXN1 protein]
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]
[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of CCL2 mRNA [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]
[1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A2 protein [1,2-dilauroylphosphatidylcholine co-treated with 1,2-oleoylphosphatidylcholine co-treated with Phosphatidylserines co-treated with Sodium Cholate] results in increased activity of CYP3A4 protein
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]
[eicosapentaenoic acid ethyl ester co-treated with Sodium Cholate co-treated with Dietary Fats] results in increased expression of IL1B mRNA [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]
MET gene mutant form affects the susceptibility to [Cholesterol, Dietary co-treated with Sodium Cholate]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of CCND1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of GCLC protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK1 protein]; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [[[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased abundance of Triglycerides]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased oxidation of Glutathione]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of ALPL protein]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased secretion of Bile Acids and Salts]; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased uptake of and results in increased oxidation of Lipids]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NFE2L2 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1H3 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of NR1I3 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of PPARA protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased expression of RARA protein]
[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SCD1 mRNA]
[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA; eicosapentaenoic acid ethyl ester inhibits the reaction [[Sodium Cholate co-treated with Dietary Fats] results in increased expression of SOAT2 mRNA]
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein; MET gene mutant form promotes the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in increased cleavage of SREBF1 protein]
[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein; MET gene mutant form inhibits the reaction [[Cholesterol, Dietary co-treated with Sodium Cholate] results in decreased expression of TRP53 protein]
ABCB11 protein affects the import of Taurocholic Acid ABCB11 protein mutant form results in decreased transport of Taurocholic Acid ABCB11 protein results in increased uptake of Taurocholic Acid Taurocholic Acid results in increased expression of ABCB11 mRNA 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] ABCB11 protein affects the transport of Taurocholic Acid 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside affects the reaction [[Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid]; [Emodin affects the activity of ABCB11 protein] which affects the export of Taurocholic Acid; GLPG1837 inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; ivacaftor inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]; Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; Troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid] Taurocholic Acid results in increased expression of ABCB11 protein ABCB11 protein affects the secretion of Taurocholic Acid ABCB11 protein results in decreased uptake of Taurocholic Acid ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid
Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form Taurocholic Acid results in increased expression of ABCC2 mRNA Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein
Taurocholic Acid results in increased activity of ABCC3 protein 4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid] ABCC3 protein affects the transport of Taurocholic Acid
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid] AHR gene mutant form results in increased secretion of Taurocholic Acid
Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]]
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein] Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]
Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]
Taurocholic Acid results in increased expression of CXCL1 mRNA [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]
Taurocholic Acid results in decreased activity of CYP3A2 protein [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Taurocholic Acid
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein] Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein
[Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA Taurocholic Acid results in increased expression of FGF15 mRNA
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein] Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of IL1B mRNA [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid IL1B protein results in decreased import of Taurocholic Acid astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; Heparin, Low-Molecular-Weight inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] IL6 protein results in decreased import of Taurocholic Acid [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA] Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]
JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein] Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein] Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Heparin, Low-Molecular-Weight inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] Taurocholic Acid results in increased expression of MPO protein
Taurocholic Acid results in increased expression of MYC protein [NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA Taurocholic Acid results in increased expression of MYC mRNA sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein
[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]
epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein NR1H4 protein affects the susceptibility to Taurocholic Acid NR1H4 protein affects the abundance of Taurocholic Acid Taurocholic Acid results in increased expression of NR1H4 mRNA Taurocholic Acid results in increased activity of NR1H4 protein [NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid Taurocholic Acid results in increased expression of NR1I3 mRNA
Taurocholic Acid results in increased activity of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]
Taurocholic Acid results in increased expression of PTGS2 mRNA Taurocholic Acid results in increased expression of PTGS2 protein JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] Taurocholic Acid results in increased phosphorylation of RELA protein Taurocholic Acid affects the localization of RELA protein modified form JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]
S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein
[Cyclosporine results in decreased activity of SLC10A1 protein] which results in decreased uptake of Taurocholic Acid; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLC10A1 mRNA 4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid promotes the reaction [SLC10A1 protein results in increased uptake of Fluorescein-5-isothiocyanate]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]
Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid] Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid]
Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate] Taurocholic Acid results in decreased activity of SLC19A1 protein
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid]
[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid]
Bile Acids and Salts inhibits the reaction [SLCO1A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLCO1A1 protein results in increased uptake of perfluorooctanoic acid]
SLCO1A4 protein affects the uptake of Taurocholic Acid Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLCO1A4 mRNA SLCO1A4 protein affects the transport of Taurocholic Acid
Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid] Taurocholic Acid results in increased expression of SLCO1B2 mRNA Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
SLCO2B1 protein results in increased uptake of Taurocholic Acid Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid]
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] Taurocholic Acid results in increased expression of SOD2 mRNA astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
Taurocholic Acid results in increased phosphorylation of STAT1 protein rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein]
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Heparin, Low-Molecular-Weight inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA] TNF protein results in decreased transport of Taurocholic Acid TNF protein results in decreased import of Taurocholic Acid [TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA] Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA] Taurocholic Acid results in decreased expression of VCAM1 protein
browse the term
